Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Kang, Wei ^a   Tong, Joanna H M ^a   Chan, Anthony W H ^a   Lung, Raymond W M ^a   Chau, Shuk Ling ^a   Wong, Queenie W L ^a   Wong, Nathalie ^a   Yu, Jun ^a,b   Cheng, Alfred S L ^a,b   To, Ka Fai ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 223; PROTEIN P53; STATHMIN; STATHMIN 1; UNCLASSIFIED DRUG; MIRN223 MICRORNA, HUMAN; SMALL INTERFERING RNA; STMN1 PROTEIN, HUMAN;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL INVASION; COLONY FORMATION; CONTROLLED STUDY; CORRELATION FUNCTION; GENETIC REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; QUALITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; AGED; CELL MOTION; DRUG ANTAGONISM; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENETICS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RNA INTERFERENCE; STOMACH TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; AGED; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STATHMIN; STOMACH NEOPLASMS;

EID: 84859089866     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033919     Document Type: Article

References (43)

1. Brenner H, Rothenbacher D, Arndt V, (2009) Epidemiology of stomach cancer. Methods Mol Biol 472: 467-477.
2. Smith MG, Hold GL, Tahara E, El-Omar EM, (2006) Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12: 2979-2990.
3. Leung WK, Wu KC, Wong CY, Cheng AS, Ching AK, et al. (2008) Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis 29: 1648-1654.
4. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, et al. (2009) Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136: 640-651 e641.
5. Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, et al. (2005) Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13: 937-941.
6. Cheng YY, Yu J, Wong YP, Man EP, To KF, et al. (2007) Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 97: 895-901.
7. Leung WK, Bai AH, Chan VY, Yu J, Chan MW, et al. (2004) Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut 53: 331-338.
8. Li J, Ng EK, Ng YP, Wong CY, Yu J, et al. (2009) Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer. Br J Cancer 101: 691-698.
9. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, et al. (2011) Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 17: 2130-2139.
10. Rubin CI, Atweh GF, (2004) The role of stathmin in the regulation of the cell cycle. J Cell Biochem 93: 242-250.
11. Alli E, Yang JM, Hait WN, (2007) Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26: 1003-1012.
12. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, et al. (2008) The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Res Treat 110: 317-326.
13. Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, et al. (2007) Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 67: 1038-1052.
14. Kim JY, Harvard C, You L, Xu Z, Kuchenbecker K, et al. (2007) Stathmin is overexpressed in malignant mesothelioma. Anticancer Res 27: 39-44.
15. Xi W, Rui W, Fang L, Ke D, Ping G, et al. (2009) Expression of stathmin/op18 as a significant prognostic factor for cervical carcinoma patients. J Cancer Res Clin Oncol 135: 837-846.
16. Wang F, Wang LX, He W, Zhu LN, Zhao PR, et al. (2010) [Expression of stathmin in esophageal squamous cell carcinoma and its biological significance]. Nan Fang Yi Ke Da Xue Xue Bao 30: 1552-1557.
17. Jeon TY, Han ME, Lee YW, Lee YS, Kim GH, et al. (2010) Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 102: 710-718.
18. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, et al. (2008) MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135: 257-269.
19. Farazi TA, Spitzer JI, Morozov P, Tuschl T, (2011) miRNAs in human cancer. J Pathol 223: 102-115.
20. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, et al. (2009) Decreased expression of microRNA-143 and-145 in human gastric cancers. Oncology 77: 12-21.
21. Du Y, Xu Y, Ding L, Yao H, Yu H, et al. (2009) Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 44: 556-561.
22. Zhang Y, Guo J, Li D, Xiao B, Miao Y, et al. (2009) Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol.
23. Xiao B, Guo J, Miao Y, Jiang Z, Huan R, et al. (2009) Detection of miR-106a in gastric carcinoma and its clinical significance. Clin Chim Acta 400: 97-102.
24. Liu T, Tang H, Lang Y, Liu M, Li X, (2009) MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 273: 233-242.
25. Johnsen JI, Aurelio ON, Kwaja Z, Jorgensen GE, Pellegata NS, et al. (2000) p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer 88: 685-691.
26. Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ, et al. (2010) Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 9: 4897-4905.
27. Hsieh SY, Huang SF, Yu MC, Yeh TS, Chen TC, et al. (2010) Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 49: 476-487.
28. Gan L, Guo K, Li Y, Kang X, Sun L, et al. (2010) Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol Rep 23: 1037-1043.
29. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, et al. (2006) Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209: 549-558.
30. Wang X, Chen Y, Han QB, Chan CY, Wang H, et al. (2009) Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics 9: 242-253.
31. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, et al. (2006) Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 94: 717-723.
32. Iancu-Rubin C, Atweh GF, (2005) p27(Kip1) and stathmin share the stage for the first time. Trends Cell Biol 15: 346-348.
33. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, et al. (2008) Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 19: 2003-2013.
34. Singer S, Malz M, Herpel E, Warth A, Bissinger M, et al. (2009) Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 69: 2234-2243.
35. Sun W, Shen W, Yang S, Hu F, Li H, et al. (2010) miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-beta. Cell Res 20: 1158-1169.
36. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, et al. (2007) An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 129: 617-631.
37. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, et al. (2008) Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451: 1125-1129.
38. Sugatani T, Hruska KA, (2007) MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem 101: 996-999.
39. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, et al. (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35.
40. Wang JF, Yu ML, Yu G, Bian JJ, Deng XM, et al. (2010) Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 394: 184-188.
41. Li X, Zhang Y, Zhang H, Liu X, Gong T, et al. (2011) miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9: 824-833.
42. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, et al. (1999) Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 18: 5954-5958.
43. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, et al. (2011) Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol.